The second day of ISDMISEHC saw a lot of engagement on social media and a lot of interest from clinicians, patients, and policymakers around the world. Professor Alex Barratt from […]
Latest articles
The BMJ Today: Patient data, sweetened drinks, and fruit juice
• Patient data from the clinical trials of statins In July 2014, an expert panel convened by The BMJ called for anonymised individual patient data from the clinical trials of statins […]
Billy Boland: Time for a new definition of quality?
I’ve been troubled by our modern concepts of quality in healthcare recently. In these austere times, we are all taking a harder look at the care we deliver and are […]
The BMJ Today: Naming, shaming, and homeopathy wars
• Homeopathy wars The Head to Head article “Should doctors recommend homeopathy?” has generated a heated online debate with 48 responses so far. More than 5000 people have responded to […]
Paul Lord: Too many “tick box” exercises
“L’enfer, c’est les autres”—Hell is others As I progress from trainee to GP, I have taken time to reflect on the process I have been through and I think this […]
Richard Smith: Making patient data available—the risks are easy to understand, the benefits opaque
“We seem to spend all our time talking about the downside of making patient data available and little about the upside,” said a frustrated researcher at last week’s Sowerby eHealth […]
Lyndal Trevena: What’s happening on Day 1 of #ISDMISEHC Sydney 2015
The first day of ISDMISEHC is over and synthesising the issues from the Twitter feed and presentations today is quite a challenge. Given that 300 people are exchanging ideas and […]
Helen Bygrave: Simple but elusive—why are we still talking about HIV drug delivery?
As the International AIDS Society (IAS) Conference takes place in Vancouver, Canada (July 19-22), Helen Bygrave of MSF discusses her frustrations with the lack of implementation of simple, programmatic strategies for improving […]
How can we improve the availability and use of health research in developing countries?
Global health is fundamentally dependent on the availability and use of health research. It is well known that much research is of poor quality, is not applicable to low-resource settings, […]
Richard Lehman’s journal review—20 July 2015
NEJM 16 July 2015 Vol 373 209 I’ll say it again: “Cancer boasts the worst trials in medicine. Also the worst drug regulation. Also the worst cost/benefit ratio for new […]